Navigation Links
Statins may Help Treat Hepatitis C Patients

A new study has demonstrated the potential of statins, used in important cholesterol management therapies, for improving the management of hepatitis C .

Statins or HMG-CoA reductase inhibitors form a class of hypolipidemic agents, used as pharmaceutical agents to lower cholesterol levels in people with or at risk for cardiovascular disease.

Two studies were conducted by a team of researchers led by Ted Bader at the University of Oklahoma in Oklahoma City to see the effect of statins.

As part of the first study, researchers conducted a 14-day study looking at the antiviral effect of fluvastatin (FLV) in vivo, in hepatitis C virus (HCV) patients who take statins, to see whether they experience any improvements in alanine transaminase (ALT, liver enzymes) levels.

The researchers reported the total bilirubin (TB, yellow breakdown product) and ALT results and compared the findings to an existing hepatitis C registry data.

Researchers found that three patients with abnormal ALTs at baseline experienced significant improvement and nine patients who started with normal ALTs stayed normal.

In addition, there were no significant changes in TB levels. No liver problems were noted despite FLV doses that were up to four times the highest FDA-approved dose.

Scientists also examined the existing HCV registry and noted both the number of patients who improved their abnormal ALT levels after statin therapy and the number of patients who maintained their normal ALT levels after initiation of statin therapy. Of the abnormal ALT group, 12 had improved ALT and one stayed unchanged. Of the 47 beginning in the normal range, 45 maintained their ALTs.

"This is the first report of prospectively using fluvastatin in HCV patients. Two remarkable observations were made and data not only supports the lack of harm in this situation, but also seems to suggest a possible salutary effect t hat needs further study," Bader said.

As part of naother study researchers retrospectively analyzed the effect of taking peginterferon and ribavirin (PI+R, hepatitis C treatment options) and PI+R plus a statin to measure the sustained viral response (SVR, negative virus in blood six months after the end of treatment) rate in hepatitis C patients.

In this study, 104 patients taking PI+R were compared to 30 patients who took PI+R plus a statin. Almost all patients (25 of the 30) taking a statin were on simvastatin, two were on lovastatin, two were on atorvastatin and one on fluvastatin.

Researchers found that the patients on standard treatment achieved a 37 percent SVR rate, the highest SVR reported to date in the medical literature for a VA-based population.

Having a high SVR rate means a cure is 95 percent of the time based upon long-term follow up that is greater than six months after treatment. The SVR rate for patients taking triple therapy, PI+R plus a statin, was 63 percent.

"It is important for statins to be studied prospectively for their effect on hepatitis C. Further study may contribute to developing a more effective outcome of treatment," Bader said.


'"/>




Related medicine news :

1. Statins reduce heart attacks
2. Statins reduce risks for angioplasty patients
3. Statins Found To Be Helpful For Patients With Arthritis
4. Long-Term Benefits Of Statins Questioned
5. Statins Not Effective In Treating Calcific Aortic Stenosis
6. Statins Gives New Hope for Increased Survival Rate of Heart Failure Patients
7. The Effects of Statins Questioned
8. Statins Taken For Reducing Cholesterol Found To Reduce Death Rate Associated With Heart Attack As Well
9. Study Finds No Link Between Statins And Breast Cancer Risk
10. Statins Reduce Deaths And Strokes After Carotid Surgery
11. Statins reduces cardiovascular risk but no cancer risk.
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/18/2017)... ... August 18, 2017 , ... August ... “Vision & Hearing,” advocating for active, healthy lifestyles and highlighting the importance of ... individuals with hearing impairments and shares the latest innovations in hearing aid technology. ...
(Date:8/18/2017)... ... August 18, 2017 , ... The Dawn Johnson Insurance Group, a ... charity drive to generate community support for efforts to educate the local population on ... for all types of cancer. , Each day in America, roughly 4,600 new ...
(Date:8/18/2017)... ... August 18, 2017 , ... Moore Insurance, a ... in east Texas, is launching a regional charity effort to provide publicity assistance ... the Pediatric Brain Tumor Foundation (PBTF) has raised nearly $30 million in donations ...
(Date:8/18/2017)... TX (PRWEB) , ... August 18, 2017 , ... ... management and financial planning firm that serves residential and commercial clients in the ... charity drive to raise community support for the fight against cancer. , Founded ...
(Date:8/18/2017)... ... August 18, 2017 , ... With over 16,000 active ... hormone replacement therapy and integrative medicine, has become a frontrunner for people seeking ... as menopause, andropause, thyroid disorder and adrenal insufficiencies. , Founded in 2003 ...
Breaking Medicine News(10 mins):
(Date:8/7/2017)... Aug. 7, 2017 Diplomat Pharmacy, Inc. (NYSE: ... Saban as president, effective Aug. 7, 2017. ... decided to pursue other interests and will serve as president ... Paul has served us in multiple leadership roles since he ... Jun. 2015 and has provided decisive, strategic leadership which continues ...
(Date:8/7/2017)... 2017  Endo International plc (NASDAQ: ENDP ... virtually all known U.S. mesh product liability claims and ... known remaining U.S. claims at reasonable values. Under the ... fourth quarter of 2017 and continuing through the fourth ... 2017 results, the Company intends to increase its mesh ...
(Date:8/4/2017)... , Aug. 3, 2017  Agragen, LLC, ... company active in the biopharmaceutical, nutraceutical, and aquacultural ... development of its lead drug candidates, AGR131.  This ... proinflammatory cytokine from the blood of patients suffering ... and inflammatory bowel disease. ...
Breaking Medicine Technology: